Health Reading List | May 08, 2015 |
Wonderous Friday to all,
Another week without a focus or theme, but there was some exciting stuff out of the ATA Conference (I didn't include any of it because there has been so much telemedicine news recently) and there were some super meaty reports from LEK and PwC around medtech and life sciences trends. So enjoy and as always, have a great weekend!
Stay positive,
Scott
Startup Highlight: Flatiron
As we start mapping everyone's genes and giving everyone incredibly personalized medicine (specifically in oncology), firm's like Flatiron will become incredibly important.
"[Flatiron] is building data pipelines, infrastructure and software to provide cancer centers, physicians, researchers and patients with the critical insights they need to make informed decisions. Through our OncologyCloud™ platform, we're building the most comprehensive system of oncology data intelligence in the US. [Their] investors include Google Ventures, First Round Capital, and LabCorp."
As always, if you come across news, announcements, videos, or podcasts that you think everyone else would benefit from, e-mail me at scott.munro@startupdigestmail.com or tweet @R_Scott_Munro. | Hiring? Access 250+ new candidates every Monday.  Great companies are built with great teams. With Hired, access over 250 pre-screened developers, designers, and tech sales professionals every week all ready to explore new opportunities. Use Hired to find the best talent in tech so you can focus on what you do best. Sign up and make the key hires you need. | | Jonas Funk, Bob Lavoie, Lucas Pain and Monish Rajpal - LEK Consulting LEK generally has great industry reports for MedTech and Pharma, and this one is no exception. If you work in or around Health Care, I would always recommend perusing LEKs findings and seeing how they impact you or your work. | | Dimitri Drone - PwC "Q1 2015 was a record-breaking quarter with 35 deals completed representing deal value of $166.3 billion, a value higher than 2014 total deals alone." | | Ed Silverman - WSJ The implications of the Amarin suit against the FDA cannot be understated. Although physicians discuss off label uses today (and many firms get away with off label discussions), if Amarin's suit is successful, Pharma marketing will become the wild wild west. | | Jonah Comstock - MobiHealth News Our health data may extend beyond our heart rate, and blood pressure, and include information epidemiologists can glean from the bread crumbs we leave in our digital lives. If people were already scared of the amount of data we are collecting about ourselves, they will be terrified now. | | Antonio Regalado - MIT Technology Review I have purposefully stayed away from including much of the health related Apple news. Because it's been everywhere. But this Apple news is truly cool. So check it out. | | Dr. Stephen Soumerai and Dr. Ross Koppel - The Incidental Economist "The following is a guest post from Dr. Stephen Soumerai and Dr. Ross Koppel about a study of Pioneer ACOs recently published in the New England Journal of Medicine, which Austin summarized here. Dr. Soumerai is a professor at Harvard Medical School and the Harvard Pilgrim Health Care Institute. Dr. Koppel is a professor of sociology at the University of Pennsylvania and conducts health-care research at Penn and Harvard." | | Varun Saxena - Fierce Pharma In my day job I think a lot about the bloat of Pharma and MedTech sales, it is incredibly interesting to see where Smith & Nephew are going especially as firms like VuMedi try to solve the issue of overspending on Pharma sales. | | Atul Gawande - New Yorker With all the news about genetic testing (thanks Mark Cuban), and data gathering, Atul Gawande asks us to step back and ask us whether we are overtesting, and thus overpaying in our health system. A great read.
| | | You are receiving this email because you believe that the best startup articles and videos are made by active members of the startup community. © 2009-2015 Startup Digest. Startup Digest is a registered trademark of Startup Weekend. All rights reserved. | | |
No comments:
Post a Comment